@article{10902/35276,
year = {2021},
url = {https://hdl.handle.net/10902/35276},
abstract = {Diabetic cardiomyopathy is the leading cause of death among people with diabetes. Despite its severity and poor prognosis, there are currently no
approved specific drugs to prevent or even treat diabetic cardiomyopathy. There is a need to understand the pathogenic mechanisms underlying the development of diabetic cardiomyopathy to design new therapeutic strategies.
These mechanisms are complex and intricate and include metabolic dysregulation,
inflammation, oxidative stress, fibrosis, and apoptosis. Sirtuins, a group of
deacetylase enzymes, play an important role in all these processes and are,
therefore, potential molecular targets for treating this disease. In this review,
we discuss the role of sirtuins in the heart, focusing on their contribution to
the pathogenesis of diabetic cardiomyopathy and how their modulation could
be therapeutically useful.},
organization = {We apologize to the contributors to the field whose work is not cited here owing to space restrictions. We thank the Language
Advisory Service of the University of Barcelona for their assistance. The authors have received funding from the Spanish
Ministry of Economy and Competitiveness (RTI2018-093999-B-100), the ‘Fundació La Marató de TV3’, the CERCA
Programme/Generalitat de Catalunya and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM; CB07/
08/0003) to M.V-C, and from the Instituto de Salud Carlos III (PI 18/00543 and INNVAL 18/20) to J.F.N. CIBERDEM is an
initiative of the Instituto de Salud Carlos III (ISCIII) - Ministry of Economy and Competitiveness},
publisher = {Elsevier Science},
publisher = {Trends in Molecular Medicine, 2021, 27(6), 554-571},
title = {Sirtuins: to be or not to be in diabetic cardiomyopathy},
author = {Palomer, Xavier and Aguilar-Recarte, David and García López, Raquel and Nistal Herrera, Juan Francisco and Vázquez-Carrera, Manuel},
}